Scalper1 News
The last couple weeks on the market have been punishing for formerly highflying drug and device stocks. But one common side effect of lower valuations is more buyouts, which fanned a fair bit of Wall Street chatter and speculation this week. Here are the three getting the most attention. The most likely to be true: on Friday afternoon, Bloomberg reported that Baxalta (BXLT), the recently spun-off biopharma arm of Baxter International (BAX), is Scalper1 News
Scalper1 News